• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Next generation lung cancer mice model for conquering cancer stem

Research Project

Project/Area Number 15H04830
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Research Field Respiratory organ internal medicine
Research InstitutionOkayama University

Principal Investigator

Kiura Katsuyuki  岡山大学, 大学病院, 教授 (10243502)

Co-Investigator(Kenkyū-buntansha) 大橋 圭明  岡山大学, 大学病院, 講師 (60729193)
久保 寿夫  岡山大学, 大学病院, 助教 (90726928)
Research Collaborator Yoshida Tadashi  
Takata Minoru  
Project Period (FY) 2015-04-01 – 2019-03-31
Project Status Completed (Fiscal Year 2018)
Budget Amount *help
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2018: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2017: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2016: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2015: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Keywords肺癌 / EGFR変異 / 癌幹細胞 / 遺伝子改変マウスモデル / 非小細胞癌 / 肺癌幹細胞 / 臨床呼吸器学 / 呼吸器の腫瘍 / EGFR肺癌 / 内科 / 非小細胞肺癌
Outline of Final Research Achievements

NSCLC harboring EGFR mutations represents one of the most critical subgroups of the cancer in clinical practice.EGFR tyrosine-kinase inhibitors (EGFR-TKIs) are highly effective, but drug-resistance inevitably develops in the tumors. Therefore to achieve deeper and longer remission, an alternative treatment strategy is required for lung cancers harboring EGFR mutations.
Lung tumors from the transgenic mouse strains were transplanted subcutaneously into C57BL/6J. The tumors maintained EGFR-dependency, and thus the EGFR-TKI gefitinib inhibited tumor growth; however, similar to human lung cancers, the tumors acquired resistance in 60 days, following gefitinib administration. Secondary EGFR T790M mutation in the tumors developed.
These syngeneic lung-cancer mouse models harboring EGFR mutations are suitable for studying the drug-resistance mechanisms and the role of the tumor microenvironment.

Academic Significance and Societal Importance of the Research Achievements

EGFR遺伝子の変異は非喫煙者に発生する肺癌の原因として最も高頻度であり、EGFR阻害薬が有効である。しかしながら1年程度で耐性化し、根治には至らない。なぜ耐性化するかを基礎的に解明し、原因に沿った新規治療法の開発を目指すため、よりヒト肺癌に近似した肺癌マウスモデルの作製をおこなった。遺伝子改変マウスから肺癌を摘出し、他のマウスへ移植し、どのようにEGFR-TKIに対して耐性化して進展するかを評価したところヒト肺癌と近似した耐性機序を呈することが分かった。このマウスモデルをプラットフォームとして免疫療法など新規治療法の開発が期待される。

Report

(5 results)
  • 2018 Annual Research Report   Final Research Report ( PDF )
  • 2017 Annual Research Report
  • 2016 Annual Research Report
  • 2015 Annual Research Report
  • Research Products

    (43 results)

All 2019 2018 2017 2016 2015

All Journal Article (30 results) (of which Int'l Joint Research: 4 results,  Peer Reviewed: 30 results,  Open Access: 5 results,  Acknowledgement Compliant: 1 results) Presentation (13 results) (of which Int'l Joint Research: 11 results)

  • [Journal Article] Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol.2019

    • Author(s)
      Ninomiya T, Ishikawa N, Inoue K, Kubo T, Yasugi M, Shibayama T, Maeda T, Fujitaka K, Kodani M, Yokoyama T, Kuyama S, Ochi N, Ueda Y, Miyoshi S, Kozuki T, Amano Y, Kubota T, Sugimoto K, Bessho A, Ishii T, Watanabe K, Oze I, Hotta K, Kiura K.
    • Journal Title

      Clin Lung Cancer.

      Volume: 29 Issue: 2 Pages: 134-138

    • DOI

      10.1016/j.cllc.2018.10.008

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice.2019

    • Author(s)
      Hotta K, Ninomiya K, Ichihara E, Kiura K.
    • Journal Title

      Int J Clin Oncol.

      Volume: 24 Issue: 1 Pages: 41-45

    • DOI

      10.1007/s10147-018-1344-x

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed
  • [Journal Article] A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.2018

    • Author(s)
      Oda N, Hotta K, Ninomiya K, Minami D, Ichihara E, Murakami T, Yokoyama T, Ichikawa H, Chikamori K, Takigawa N, Ochi N, Harita S, Maeda Y, Kiura K.
    • Journal Title

      Cancer Chemother Pharmacol.

      Volume: 82 Issue: 6 Pages: 1031-1038

    • DOI

      10.1007/s00280-018-3694-5

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors.2018

    • Author(s)
      Kubo T, Ninomiya T, Hotta K, Kozuki T, Toyooka S, Okada H, Fujiwara T, Udono H, Kiura K.
    • Journal Title

      Clin Lung Cancer.

      Volume: 19 Issue: 6 Pages: e861-e864

    • DOI

      10.1016/j.cllc.2018.07.010

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions2018

    • Author(s)
      Kato Yuka、Ninomiya Kiichiro、Ohashi Kadoaki、Tomida Shuta、Makimoto Go、Watanabe Hiromi、Kudo Kenichiro、Matsumoto Shingo、Umemura Shigeki、Goto Koichi、Ichihara Eiki、Ninomiya Takashi、Kubo Toshio、Sato Akiko、Hotta Katsuyuki、Tabata Masahiro、Toyooka Shinichi、Maeda Yoshinobu、Kiura Katsuyuki
    • Journal Title

      Cancer Science

      Volume: 109 Issue: 10 Pages: 3149-3158

    • DOI

      10.1111/cas.13752

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M.2018

    • Author(s)
      Senoo S, Ohashi K, Nishii K, Hara N, Kano H, Ninomiya K, Maeda Y, Kiura K.
    • Journal Title

      J Thorac Oncol.

      Volume: 13 Issue: 8 Pages: e140-e142

    • DOI

      10.1016/j.jtho.2018.03.016

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer2018

    • Author(s)
      Ichihara Eiki、Hotta Katsuyuki、Kubo Toshio、Higashionna Tsukasa、Ninomiya Kiichiro、Ohashi Kadoaki、Tabata Masahiro、Maeda Yoshinobu、Kiura Katsuyuki
    • Journal Title

      Oncotarget

      Volume: 9 Issue: 50 Pages: 29525-29531

    • DOI

      10.18632/oncotarget.25705

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Needle wash solution cultures following EBUS-TBNA with or without endobronchial intubation.2018

    • Author(s)
      Minami D, Takigawa N, Oki M, Saka H, Shibayama T, Kiura K.
    • Journal Title

      Respir Investig.

      Volume: 56 Issue: 4 Pages: 356-360

    • DOI

      10.1016/j.resinv.2018.03.006

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset2018

    • Author(s)
      Kiura Katsuyuki、Imamura Fumio、Kagamu Hiroshi、Matsumoto Shingo、Hida Toyoaki、Nakagawa Kazuhiko、Satouchi Miyako、Okamoto Isamu、Takenoyama Mitsuhiro、Fujisaka Yasuhito、Kurata Takayasu、Ito Masayuki、Tokushige Kota、Hatano Ben、Nishio Makoto
    • Journal Title

      Japanese Journal of Clinical Oncology

      Volume: 48 Issue: 4 Pages: 367-375

    • DOI

      10.1093/jjco/hyy016

    • Related Report
      2018 Annual Research Report 2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery2018

    • Author(s)
      Makimoto Go、Kubo Toshio、Oze Isao、Ohashi Kadoaki、Hotta Katsuyuki、Tabata Masahiro、Soh Junichi、Toyooka Shinichi、Katsui Kuniaki、Takigawa Nagio、Tanimoto Mitsune、Kiura Katsuyuki
    • Journal Title

      Japanese Journal of Clinical Oncology

      Volume: 48 Issue: 3 Pages: 287-290

    • DOI

      10.1093/jjco/hyy003

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib2018

    • Author(s)
      Ninomiya Kiichiro、Ohashi Kadoaki、Makimoto Go、Tomida Shuta、Higo Hisao、Kayatani Hiroe、Ninomiya Takashi、Kubo Toshio、Ichihara Eiki、Hotta Katsuyuki、Tabata Masahiro、Maeda Yoshinobu、Kiura Katsuyuki
    • Journal Title

      Scientific Reports

      Volume: 8 Issue: 1 Pages: 1955-1955

    • DOI

      10.1038/s41598-018-20326-z

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples2018

    • Author(s)
      Kiura Katsuyuki、Yoh Kiyotaka、Katakami Nobuyuki、Nogami Naoyuki、Kasahara Kazuo、Takahashi Toshiaki、Okamoto Isamu、Cantarini Mireille、Hodge Rachel、Uchida Hirohiko
    • Journal Title

      Cancer Science

      Volume: 109 Issue: 4 Pages: 1177-1184

    • DOI

      10.1111/cas.13511

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR -Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results2018

    • Author(s)
      Reck Martin、Garon Edward B.、Paz-Ares Luis、Ponce Santiago、Jaime Jesus Corral、Juan Oscar、Nadal Ernest、Kiura Katsuyuki、Widau Ryan C.、He Shuang、Dalal Rita、Lee Pablo、Nakagawa Kazuhiko
    • Journal Title

      Clinical Lung Cancer

      Volume: 19 Issue: 3 Pages: 213-220.e4

    • DOI

      10.1016/j.cllc.2017.11.003

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer2018

    • Author(s)
      Hotta Katsuyuki、Aoe Keisuke、Kozuki Toshiyuki、Ohashi Kadoaki、Ninomiya Kiichiro、Ichihara Eiki、Kubo Toshio、Ninomiya Takashi、Chikamori Kenichi、Harada Daijiro、Nogami Naoyuki、Hirata Taizo、Hinotsu Shiro、Toyooka Shinichi、Kiura Katsuyuki
    • Journal Title

      Journal of Thoracic Oncology

      Volume: 13 Issue: 2 Pages: 273-279

    • DOI

      10.1016/j.jtho.2017.10.032

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.2018

    • Author(s)
      Ninomiya T, Nogami N, Kozuki T, Harada D, Kubo T, Ohashi K, Kuyama S, Kudo K, Bessho A, Fukamatsu N, Fujimoto N, Aoe K, Shibayama T, Sugimoto K, Takigawa N, Hotta K, Kiura K.
    • Journal Title

      Lung Cancer.

      Volume: 115 Pages: 103-108

    • DOI

      10.1016/j.lungcan.2017.11.025

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations.2018

    • Author(s)
      Tamura T, Kato Y, Ohashi K, Ninomiya K, Makimoto G, Gotoda H, Kubo T, Ichihara E, Tanaka T, Ichimura K, Maeda Y, Hotta K, Kiura K.
    • Journal Title

      Biochem Biophys Res Commun.

      Volume: 495 Issue: 1 Pages: 360-367

    • DOI

      10.1016/j.bbrc.2017.10.175

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 12022017

    • Author(s)
      Kuyama Shoichi、Ochi Nobuaki、Bessho Akihiro、Hotta Katsuyuki、Ikeda Genyo、Kishino Daizo、Kubo Toshio、Harada Daijiro、Fujimoto Nobukazu、Nakanishi Masamoto、Umeno Takahiro、Okada Toshiaki、Chikamori Kenichi、Yamagishi Tomoko、Ohashi Kadoaki、Ichihara Eiki、Takigawa Nagio、Tanimoto Mitsune、Kiura Katsuyuki
    • Journal Title

      Lung Cancer

      Volume: 112 Pages: 188-194

    • DOI

      10.1016/j.lungcan.2017.08.010

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Clinical characteristics of Japanese candidates for lung transplant for interstitial lung disease and risk factors for early death while on the waiting list2017

    • Author(s)
      Higo Hisao、Kurosaki Takeshi、Ichihara Eiki、Kubo Toshio、Miyoshi Kentaroh、Otani Shinji、Sugimoto Seiichiro、Yamane Masaomi、Miyahara Nobuaki、Kiura Katsuyuki、Miyoshi Shinichiro、Oto Takahiro
    • Journal Title

      Respiratory Investigation

      Volume: 55 Issue: 4 Pages: 264-269

    • DOI

      10.1016/j.resinv.2017.03.002

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial2017

    • Author(s)
      Shaw Alice T、Kim Tae Min、Crino Lucio、Gridelli Cesare、Kiura Katsuyuki、Liu Geoffrey、Novello Silvia、Bearz Alessandra、Gautschi Oliver、Mok Tony、Nishio Makoto、Scagliotti Giorgio、Spigel David R、Deudon Stephanie、Zheng Cheng、Pantano Serafino、Urban Patrick、Massacesi Cristian、et al.
    • Journal Title

      The Lancet Oncology

      Volume: 18 Issue: 7 Pages: 874-886

    • DOI

      10.1016/s1470-2045(17)30339-x

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.2017

    • Author(s)
      Kudo K, Ohashi K, Makimoto G, Higo H, Kato Y, Kayatani H, Kurata Y, Takami Y, Minami D, Ninomiya T, Kubo T, Ichihara E, Sato A, Hotta K, Yoshino T, Tanimoto M, Kiura K.
    • Journal Title

      Mol Oncol

      Volume: Epub Issue: 6 Pages: 670-681

    • DOI

      10.1002/1878-0261.12063

    • Related Report
      2017 Annual Research Report 2016 Annual Research Report
    • Peer Reviewed / Open Access / Acknowledgement Compliant
  • [Journal Article] Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset2017

    • Author(s)
      Hida Toyoaki、Satouchi Miyako、Nakagawa Kazuhiko、Seto Takashi、Matsumoto Shingo、Kiura Katsuyuki、Nokihara Hiroshi、Murakami Haruyasu、Tokushige Kota、Hatano Ben、Nishio Makoto
    • Journal Title

      Japanese Journal of Clinical Oncology

      Volume: 47 Issue: 7 Pages: 618-624

    • DOI

      10.1093/jjco/hyx045

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP2017

    • Author(s)
      Tamura Tomohide、Kiura Katsuyuki、Seto Takashi、Nakagawa Kazuhiko、Maemondo Makoto、Inoue Akira、Hida Toyoaki、Yoshioka Hiroshige、Harada Masao、Ohe Yuichiro、Nogami Naoyuki、Murakami Haruyasu、Kuriki Hiroshi、Shimada Tadashi、Tanaka Tomohiro、Takeuchi Kengo、Nishio Makoto
    • Journal Title

      Journal of Clinical Oncology

      Volume: 35 Issue: 14 Pages: 1515-1521

    • DOI

      10.1200/jco.2016.70.5749

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Study about the Efficacy of Metformin to Immune Function in Cancer Patients.2016

    • Author(s)
      Watanabe M, Yamamoto H, Eikawa S, Shien K, Shien T, Soh J, Hotta K, Wada J, Hinotsu S, Fujiwara T, Kiura K, Doihara H, Miyoshi S, Udono H, Toyooka S.
    • Journal Title

      Acta Med Okayama.

      Volume: 70 Pages: 327-30

    • NAID

      120005828926

    • Related Report
      2016 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer.2016

    • Author(s)
      Ochi N, Isozaki H, Takeyama M, Singer JW, Yamane H, Honda Y, Kiura K, Takigawa N.
    • Journal Title

      Exp Cell Res.

      Volume: 344 Issue: 2 Pages: 194-200

    • DOI

      10.1016/j.yexcr.2016.05.008

    • Related Report
      2016 Annual Research Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.2016

    • Author(s)
      Kudo K, Hotta K, Bessho A, Nogami N, Kozuki T, Kuyama S, Inoue K, Harita S, Okada T, Gemba K, Fujii M, Takigawa N, Oda N, Tanimoto M, Kiura K.
    • Journal Title

      Cancer Chemother Pharmacol.

      Volume: 77 Issue: 5 Pages: 1005-9

    • DOI

      10.1007/s00280-015-2910-9

    • Related Report
      2016 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Chemotherapy for lung cancer: still alive!2015

    • Author(s)
      Katsuyuki Kiura
    • Journal Title

      Japanese Journal of Clinical Oncology

      Volume: 45 Issue: 7 Pages: 609-610

    • DOI

      10.1093/jjco/hyv074

    • Related Report
      2015 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703.2015

    • Author(s)
      Kudo K, Hotta K, Ichihara E, Yoshioka H, Kunimasa K, Tsubouchi K, Iwasaku M, Kato Y, Oze I, Takigawa N, Tanimoto M, Kiura K.
    • Journal Title

      Cancer Chemother Pharmacol.

      Volume: 76 Issue: 2 Pages: 251-256

    • DOI

      10.1007/s00280-015-2789-5

    • Related Report
      2015 Annual Research Report
    • Peer Reviewed
  • [Journal Article] TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells2015

    • Author(s)
      Otani H, Yamamoto H, Takaoka M, Sakaguchi M, Soh J, Jida M, Ueno T, Kubo T, Asano H, Tsukuda K, Kiura K, Hatakeyama S, Kawahara E, Naomoto Y, Miyoshi S, Toyooka S
    • Journal Title

      PLoS One

      Volume: 10 Issue: 6 Pages: e0129838-e0129838

    • DOI

      10.1371/journal.pone.0129838

    • Related Report
      2015 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.2015

    • Author(s)
      Kato T, Yoshioka H, Okamoto I, Yokoyama A, Hida T, Seto T, Kiura K, Massey D, Seki Y, Yamamoto N.
    • Journal Title

      Cancer Sci.

      Volume: 106 Issue: 9 Pages: 1202-1211

    • DOI

      10.1111/cas.12723

    • Related Report
      2015 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol.2015

    • Author(s)
      Hotta K, Sasaki J, Saeki S, Takigawa N, Katsui K, Takayama K, Nogami N, Shioyama Y, Bessho A, Kishimoto J, Tanimoto M, Kiura K, Ichinose Y.
    • Journal Title

      Clin Lung Cancer.

      Volume: 17 Issue: 1 Pages: 75-79

    • DOI

      10.1016/j.cllc.2015.08.004

    • Related Report
      2015 Annual Research Report
    • Peer Reviewed
  • [Presentation] The novel osimertinib resistant lung cancer mice model harboring EGFR mutations driven by the SP-C promoter2018

    • Author(s)
      Kadoaki Ohashi, Hisao Higo, Go Makimoto, Kenichiro Kudo, Kazuya Nishii, Kiichiro Ninomiya, Hiroe Kayatani, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura
    • Organizer
      AACR Annual Meeting 2018
    • Related Report
      2018 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Novel Syngenic Lung Cancer Mouse Model Harboring EGFR Mutations2018

    • Author(s)
      Kazuya Nishii, Kadoaki Ohashi, Hisao Higo, Kenichiro Kudo, Go Makimoto, Hiroe Kayatani, Hiromi Watanabe, Kiichiro Ninomiya, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura
    • Organizer
      The 6th JCA-AACR Special Joint Conference
    • Related Report
      2018 Annual Research Report
    • Int'l Joint Research
  • [Presentation] In vivo efficacy of triplet therapy with osimertinib, cetuximab and bevacizumab for lung cancer cells harboring EGFR T790M2018

    • Author(s)
      Kazuya Nishii, Kadoaki Ohashi, Go Makimoto, Hisao Higo, Kiichiro Ninomiya, Hiroe Kayatani, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura
    • Organizer
      AACR Annual Meeting 2018
    • Related Report
      2018 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Analysis of the Rapid Acquired Resistance of ALK-positive Lung Cancers to Alectinib: A Comprehensive Study Using Autopsied Specimens and Patient-derived Cell Lines2018

    • Author(s)
      Go Makimoto, Kadoaki Ohashi, Kazuya Nishii, (Shuta Tomida), Hiroe Kayatani, Hisao Higo, Kiichiro Ninomiya, Hiromi Watanabe, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, (Sinichi Toyooka), Yoshinobu Maeda, Katsuyuki Kiura
    • Organizer
      The 6th JCA-AACR Special Joint Conference
    • Related Report
      2018 Annual Research Report
    • Int'l Joint Research
  • [Presentation] EGFR変異陽性NSCLCに対するafatinib・bevacizumab併用療法の第I相試験:OLCSG14042018

    • Author(s)
      青江 啓介、近森 研一、前田 忠士、亀井 治人、二宮 崇、野上 尚之、別所 昭宏、久山 彰一、藤本 伸一、杉本 啓介、瀧川 奈義夫、木浦 勝行
    • Organizer
      第58回日本呼吸器学会学術講演会
    • Related Report
      2018 Annual Research Report
  • [Presentation] Acquired resistance to the third-generation EGFR inhibitor ASP8273 is associated with MET or NRAS gene amplifications in preclinical models2017

    • Author(s)
      Kiichiro Ninomiya, Kadoaki Ohashi, Shuta Tomida, Hiroe Kayatani, Tomoki Tamura, Hisao Higo, Go Makimoto, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura.
    • Organizer
      AACR Annual Meeting 2017
    • Related Report
      2017 Annual Research Report
    • Int'l Joint Research
  • [Presentation] A comprehensive analysis of autopsied specimens and patient-derived cell lines in ALK-positive lung cancers with rapid acquired resistance to alectinib2017

    • Author(s)
      Go Makimoto, Kadoaki Ohashi, Kazuya Nishii, Shuta Tomida, Hiroe Kayatani, Tomoki Tamura, Hisao Higo, Kiichiro Ninomiya, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura
    • Organizer
      AACR Annual Meeting 2017
    • Related Report
      2017 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Clinical Characteristics of Japanese Candidates for Lung Transplant Due to Interstitial Lung Disease and Risk Factors for Early Death While on the Waiting List2017

    • Author(s)
      Hisao Higo , Eiki Ichihara , Takeshi Kurosaki , Kentaroh Miyoshi , Toshio Kubo , Shinji Otani , Seiichiro Sugimoto , Masaomi Yamane , Nobuaki Miyahara , Katsuyuki Kiura , Takahiro Oto
    • Organizer
      American Thoracic Society 2017 International Conference
    • Related Report
      2017 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Abstract 250: Interleukin-6 as potential predictive marker for therapeutic effect of Gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations2016

    • Author(s)
      Tomoki Tamura, Katsuyuki Hotta, Yuka Kato, Takehiro Tanaka, Kouichi Ichimura, Kadoaki Oohashi, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Mitsune Tanimoto, Katsuyuki Kiura
    • Organizer
      AACR 2016
    • Place of Presentation
      Ernest N. Morial Convention Center New Orleans, Louisiana
    • Year and Date
      2016-04-16
    • Related Report
      2016 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Abstract 5198: Combination effect of anti-VEGFR-2 antibody with erlotinib on EGFR mutant non-small cell lung cancer2016

    • Author(s)
      Hiroe Kayatani, Kadoaki Ohashi, Takeshi Imao, Kenichiro Kudo, Yuka Kato, Takashi Ninomiya, Toshio Kubo, Akiko Sato, Ktsuyuki Hotta, Mitsune Tanimoto, Katsuyuki Kiura
    • Organizer
      AACR 2016
    • Place of Presentation
      Ernest N. Morial Convention Center New Orleans, Louisiana
    • Year and Date
      2016-04-16
    • Related Report
      2016 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Abstract 4675: Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal growth factor receptor mutation-positive non-small cell lung cancer2016

    • Author(s)
      Nobuaki Ochi, Hideko Isozaki, Masami Takeyama, Jack W. Singer, Hiromichi Yamane, Yoshihiro Honda, Katsuyuki Kiura, Nagio Takigawa
    • Organizer
      AACR 2016
    • Place of Presentation
      Ernest N. Morial Convention Center New Orleans, Louisiana
    • Year and Date
      2016-04-16
    • Related Report
      2016 Annual Research Report
  • [Presentation] Abstract 1889: AXL and EGFR signaling mediate resistance to Crizotinib in non-small cell lung cancer cells harboring the ROS1 fusion gene2016

    • Author(s)
      Yuka Kato, Kadoaki Ohashi, Eiki Ichihara, Shuuta Tomida, Hiroe Kayatani, Kenichiro Kudo, Daisuke Minami, Takashi Ninomiya, Toshio Kubo, Toshiyuki Kozuki, Katsuyuki Hotta, Nagio Takigawa, Mitsune Tanimoto, Katsuyuki Kiura
    • Organizer
      AACR 2016
    • Place of Presentation
      Ernest N. Morial Convention Center New Orleans, Louisiana
    • Year and Date
      2016-04-16
    • Related Report
      2016 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Abstract 4667: pCR induced by triplet therapy with low-dose afatinib, cetuximab and bevcizumab in lung cancer cells harboring EGFR T790M2016

    • Author(s)
      AKadoaki Ohashi, Kenichiro Kudo, Eiki Ichihara, Hiroe Kayatani, Hisao Higo, Yuka Kato, Yasuko Kurata, Daisuke Minami, Takashi Ninomiya, Toshio Kubo, Katsuyuki Hotta, Mitsune Tanimoto, Katsuyuki Kiura
    • Organizer
      AACR 2016
    • Place of Presentation
      Ernest N. Morial Convention Center New Orleans, Louisiana
    • Year and Date
      2016-04-16
    • Related Report
      2016 Annual Research Report
    • Int'l Joint Research

URL: 

Published: 2015-04-16   Modified: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi